Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Cash from Investing Activities (2020 - 2023)

Historic Cash from Investing Activities for Journey Medical (DERM) over the last 4 years, with Q1 2023 value amounting to -$5.0 million.

  • Journey Medical's Cash from Investing Activities rose 7500.0% to -$5.0 million in Q1 2023 from the same period last year, while for Dec 2023 it was -$5.0 million, marking a year-over-year increase of 7500.0%. This contributed to the annual value of -$15.0 million for FY2024, which is 20000.0% down from last year.
  • Per Journey Medical's latest filing, its Cash from Investing Activities stood at -$5.0 million for Q1 2023, which was up 7500.0% from -$20.0 million recorded in Q1 2022.
  • In the past 5 years, Journey Medical's Cash from Investing Activities ranged from a high of -$200000.0 in Q4 2020 and a low of -$20.0 million during Q1 2022
  • Its 4-year average for Cash from Investing Activities is -$6.6 million, with a median of -$3.1 million in 2021.
  • In the last 5 years, Journey Medical's Cash from Investing Activities crashed by 50000.0% in 2021 and then skyrocketed by 7500.0% in 2023.
  • Journey Medical's Cash from Investing Activities (Quarter) stood at -$200000.0 in 2020, then plummeted by 500.0% to -$1.2 million in 2021, then tumbled by 1566.67% to -$20.0 million in 2022, then skyrocketed by 75.0% to -$5.0 million in 2023.
  • Its Cash from Investing Activities was -$5.0 million in Q1 2023, compared to -$20.0 million in Q1 2022 and -$1.2 million in Q4 2021.